

Press Release

Renowned Ophthalmologists Richard L. Lindstrom and Eugene de Juan, Jr. join Refractec

Irvine, CA – Friday, December 14, 2007 – Ophthalmic device manufacturer Refractec today announced that Richard L. Lindstrom, M.D. and Eugene de Juan, Jr., M.D., internationally recognized leaders in ophthalmology, have joined Refractec as investors and have been appointed to its board of directors.

Dr. Lindstrom, president of the American Society of Cataract & Refractive Surgery, is the founder of Minnesota Eye Consultants. He is a board-certified ophthalmologist and internationally recognized leader in corneal, refractive and laser surgery. Dr. Lindstrom has been at the forefront of ophthalmology's evolutionary changes throughout his career and holds 36 patents for the design of several ophthalmic devices and instruments that are used in clinical practices worldwide. He founded the Phillips Eye Institute Center for Teaching & Research, an ophthalmic research and surgical skill education facility, and serves as the Medical Director and member of the Board of Directors of TLC Vision Corp., eyeonics, Inc., Occulogix, Inc., and AcuFocus, Inc.

Dr. de Juan is a founding member of ForSight Labs, which aims to create new companies around promising ophthalmic medical device technologies. He is the Jean Kelly Stock Distinguished Professor of Ophthalmology at the University of California at San Francisco's School of Medicine and has frequently been listed as one of the top 10 practicing ophthalmologists in the U.S. Dr de Juan has co-founded five ophthalmic device companies and holds over 40 drug and device patents.

“Drs. Lindstrom and de Juan's exceptional clinical and research backgrounds and their stature within the global ophthalmic community make them an excellent addition to our board of directors,” said Paul Ehlen, Refractec's chief executive officer. “We consider their expertise, particularly in vision-correction technologies, a tremendous asset and we are fortunate to have their counsel in the continued growth of our company. Their significant financial investment evidences their clear belief in the technology and the potential for growth in the presbyopic market.”

About Refractec

Refractec is an ophthalmic medical device company that develops and markets an innovative and proprietary radiofrequency (RF) device called the ViewPoint® CK System. The ViewPoint CK System, used to perform the NearVisionSM CK® (Conductive Keratoplasty®) treatment, is the only FDA-approved technology that temporarily improves near vision for the 37 million presbyopic emmetropes and presbyopic hyperopes in the USA, and can be conveniently performed in-office in just a few minutes. Collectively, over 200,000 CK treatments have been performed worldwide.